TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03746223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
Study: NCT02017184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Noninvasive core temperature thermistor
Study: NCT00928967

Intervention type: DRUG
Intervention: Interferon beta-1b, (Betaseron BAY86-5046)
Description: The cohort included is described in section 8.5 (inclusion criteria)
Study: NCT04104347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Description: Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
Study: NCT03166748

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate in Polycarboxylate cement
Description: The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate in Polycarboxylate cement
Description: The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity
Study: NCT03060902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills
Description: DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
Study: NCT04473560

Intervention type: DEVICE
Intervention: Catheter-directed thrombectomy
Description: Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
Study: NCT04201704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced crystalloid solution volume administration
Description: Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution volume administration
Description: Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed Erythrocytes Units, Blood Product Unit volume
Description: For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Erythrocytes Units, Blood Product Unit volume
Description: For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study: NCT03746223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
Study: NCT01797510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Based Health Coaching
Study: NCT03440255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)
Study: NCT04342182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products
Study: NCT00887146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant temozolomide (TMZ)
Description: 75 mg/m\^2, orally daily
Study: NCT04201704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma volume
Description: For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study: NCT00736944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IVPB Day 1, cycles 1, 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IVPB Day 1, cycles 1, 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Study: NCT04201704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma volume
Description: For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelets volume
Description: For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelets volume
Description: For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study: NCT01306695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI)
Description: The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease.

Intervention type: OTHER
Group type: OTHER
Intervention: Community Health Worker (CHW) Case Management
Description: The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
Study: NCT03655847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
Study: NCT03969173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: applying PEEP3
Description: The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: applying PEEP6
Description: The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
Study: NCT00887146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study: NCT03969173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: applying PEEP9
Description: The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
Study: NCT00887146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine
Description: Days 8-21: 60 mg/m\^2 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant temozolomide (TMZ)
Description: 150 or 200 mg/m\^2 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCNU
Description: Day 1: 110 mg/m\^2 orally
Study: NCT01219257

Intervention type: BIOLOGICAL
Intervention: Anti-TNF alpha therapy
Description: All medical treatment will be standardizes following good medical practice
Study: NCT01286597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary restriction
Description: restrict intake of lactose
Study: NCT02803905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: Islet transplantation
Description: This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Islet transplantation
Description: This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
Study: NCT02273089

Intervention type: DEVICE
Intervention: CPAP (ResMed S9 AutoSet)
Description: nocturnal CPAP for three months

Intervention type: DEVICE
Intervention: CPAP (ResMed S9 AutoSet)
Description: nocturnal CPAP for three months
Study: NCT01957865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed SMS, real-time monitoring
Description: SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triggered SMS, real-time monitoring
Description: SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
Study: NCT01415752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study: NCT00887146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Days 8 and 29: 1.4 mg/m\^2 IV
Study: NCT03294408

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: multimodal imaging
Study: NCT04202718

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VitalPatch Device
Description: The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
Study: NCT04389398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pocket compression fixation belt
Description: Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pocket compression fixation belt
Description: Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
Study: NCT02222389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM for Alcohol
Description: Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM for drugs
Description: Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM for both substances
Description: Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Contingent group
Description: Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
Study: NCT01415752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study: NCT00736944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Study: NCT01830738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port, peri-umbilical hysterectomy
Description: Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port hysterectomy
Description: Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
Study: NCT01983371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
Study: NCT03702647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30mL of 0.2% Ropivacaine placed in the POEM tunnel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 30mL of normal saline placed in the POEM tunnel